The Patented Medicine Prices Review Board’s (PMPRB) New Guidance for 2026

Hear the latest update on draft guidelines detailing the administrative process for recommending hearings on excessive drug pricing, to enhance transparency and procedural fairness in assessing whether a patented medicine’s price is excessive. Adopt best practices to:

• Learn directly from the PMPRB on how the draft guidelines and recommendations have been asserted.
• Gain clarity on the PMPRB’s interim guidance aimed at expediting price reviews and its impact on market entry timelines.

Master the roadmap for 2026 and beyond in PMPRB strategy to improve pricing processes and ensure timely market access for innovative medicines.